CAPOTEN 12.5 MG TABLETS
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
01-04-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
CAPTOPRIL
Available from:
Bristol-Myers Squibb Pharmaceuticals Ltd
Dosage:
12.5 Milligram
Pharmaceutical form:
Tablets
Authorization date:
1986-09-30
Summary of Product characteristics
License
IRISH MEDICINES BOARD ACTS 1995 AND 2006
MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007
(S.I. No.540 of 2007)
PA0002/039/004
Case No: 2050595
The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to
Bristol-Myers Squibb Pharmaceuticals Ltd
Swords, Co. Dublin, Ireland
an authorisation, subject to the provisions of the said Regulations, in respect of the product
Capoten 12.5 mg Tablets
The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as
may be specified in the said Regulations as listed on the reverse of this document.
This authorisation, unless previously revoked, shall continue in force from 26/03/2009.
Signed on behalf of the Irish Medicines Board this
________________
A person authorised in that behalf by the said Board.
Irish Medicines Board
______________________________________________________________________________________________________________________
Date Printed 26/03/2009
CRN 2050595
page number: 1
Part II
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
Capoten 12.5 mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains captopril
12.5 mg
Excipients: Lactos
Read the complete document
